Pfizer announces positive top-line results from Phase 3 study of hemophilia B gene therapy candidate

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.

from Breaking World Pharma News https://ift.tt/khUa28I